# An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy

> **NCT03279263** · PHASE2 · UNKNOWN · sponsor: **Melior Pharmaceuticals** · enrollment: 400 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** MLR-1023
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03279263
- **Lead sponsor:** Melior Pharmaceuticals
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2019-09
- **Final completion:** 2019-09
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2019-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03279263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03279263, "An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03279263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*